203 related articles for article (PubMed ID: 31022852)
1. [
Amor-Coarasa A; Kelly JM; Singh PK; Ponnala S; Nikolopoulou A; Williams C; Vedvyas Y; Jin MM; Warren JD; Babich JW
Molecules; 2019 Apr; 24(8):. PubMed ID: 31022852
[TBL] [Abstract][Full Text] [Related]
2. [
Amor-Coarasa A; Kelly J; Ponnala S; Vedvyas Y; Nikolopoulou A; Williams C; Jin MM; David Warren J; Babich JW
Nucl Med Biol; 2018 May; 60():37-44. PubMed ID: 29544122
[TBL] [Abstract][Full Text] [Related]
3. High-Contrast CXCR4-Targeted
Kwon D; Lozada J; Zhang Z; Zeisler J; Poon R; Zhang C; Roxin Á; Lin KS; Perrin D; Benard F
Mol Pharm; 2021 Jan; 18(1):187-197. PubMed ID: 33253591
[TBL] [Abstract][Full Text] [Related]
4. (68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma.
Lapa C; Lückerath K; Kleinlein I; Monoranu CM; Linsenmann T; Kessler AF; Rudelius M; Kropf S; Buck AK; Ernestus RI; Wester HJ; Löhr M; Herrmann K
Theranostics; 2016; 6(3):428-34. PubMed ID: 26909116
[TBL] [Abstract][Full Text] [Related]
5. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Evaluation of [
Peng T; Wang X; Li Z; Bi L; Gao J; Yang M; Wang Y; Yao X; Shan H; Jin H
Mol Pharm; 2021 Sep; 18(9):3638-3648. PubMed ID: 34424706
[TBL] [Abstract][Full Text] [Related]
7. [
Lapa C; Schreder M; Schirbel A; Samnick S; Kortüm KM; Herrmann K; Kropf S; Einsele H; Buck AK; Wester HJ; Knop S; Lückerath K
Theranostics; 2017; 7(1):205-212. PubMed ID: 28042328
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, Screening, and Evaluation of Theranostic Molecular CPCR4-Based Probe Targeting CXCR4.
Yang T; Shi D; Lin Q; Shen H; Tan H; Liu Y; Shi H; Cheng D
Mol Pharm; 2024 May; 21(5):2415-2424. PubMed ID: 38606663
[TBL] [Abstract][Full Text] [Related]
9. A Rapid and Specific HPLC Method to Determine Chemical and Radiochemical Purity of [
Migliari S; Sammartano A; Scarlattei M; Baldari G; Silva C; Ruffini L
Curr Radiopharm; 2021; 14(2):121-130. PubMed ID: 32990551
[TBL] [Abstract][Full Text] [Related]
10. Second generation Al
Spahn MA; Luyten K; Van Loy T; Sathekge M; Deroose CM; Koole M; Schols D; Vanduffel W; De Vos K; Annaert P; Bormans G; Cleeren F
Nucl Med Biol; 2024; 132-133():108906. PubMed ID: 38518400
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
12. [
Lau J; Kwon D; Rousseau E; Zhang Z; Zeisler J; Uribe CF; Kuo HT; Zhang C; Lin KS; Bénard F
Mol Pharm; 2019 Nov; 16(11):4688-4695. PubMed ID: 31545614
[TBL] [Abstract][Full Text] [Related]
13. Imaging of C-X-C Motif Chemokine Receptor CXCR4 Expression After Myocardial Infarction With [
Reiter T; Kircher M; Schirbel A; Werner RA; Kropf S; Ertl G; Buck AK; Wester HJ; Bauer WR; Lapa C
JACC Cardiovasc Imaging; 2018 Oct; 11(10):1541-1543. PubMed ID: 29454781
[No Abstract] [Full Text] [Related]
14. Imaging Inflammation in Atherosclerosis with CXCR4-Directed
Kircher M; Tran-Gia J; Kemmer L; Zhang X; Schirbel A; Werner RA; Buck AK; Wester HJ; Hacker M; Lapa C; Li X
J Nucl Med; 2020 May; 61(5):751-756. PubMed ID: 31653710
[TBL] [Abstract][Full Text] [Related]
15. Comparison of (18)F-labeled CXCR4 antagonist peptides for PET imaging of CXCR4 expression.
Zhang XX; Sun Z; Guo J; Wang Z; Wu C; Niu G; Ma Y; Kiesewetter DO; Chen X
Mol Imaging Biol; 2013 Dec; 15(6):758-67. PubMed ID: 23636490
[TBL] [Abstract][Full Text] [Related]
16. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.
Werner RA; Weich A; Higuchi T; Schmid JS; Schirbel A; Lassmann M; Wild V; Rudelius M; Kudlich T; Herrmann K; Scheurlen M; Buck AK; Kropf S; Wester HJ; Lapa C
Theranostics; 2017; 7(6):1489-1498. PubMed ID: 28529632
[TBL] [Abstract][Full Text] [Related]
17. Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients.
Bluemel C; Hahner S; Heinze B; Fassnacht M; Kroiss M; Bley TA; Wester HJ; Kropf S; Lapa C; Schirbel A; Buck AK; Herrmann K
Clin Nucl Med; 2017 Jan; 42(1):e29-e34. PubMed ID: 27819856
[TBL] [Abstract][Full Text] [Related]
18. Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia.
Herhaus P; Habringer S; Philipp-Abbrederis K; Vag T; Gerngross C; Schottelius M; Slotta-Huspenina J; Steiger K; Altmann T; Weißer T; Steidle S; Schick M; Jacobs L; Slawska J; Müller-Thomas C; Verbeek M; Subklewe M; Peschel C; Wester HJ; Schwaiger M; Götze K; Keller U
Haematologica; 2016 Aug; 101(8):932-40. PubMed ID: 27175029
[TBL] [Abstract][Full Text] [Related]
19. Fluorine-18 click radiosynthesis and preclinical evaluation of a new 18F-labeled folic acid derivative.
Ross TL; Honer M; Lam PY; Mindt TL; Groehn V; Schibli R; Schubiger PA; Ametamey SM
Bioconjug Chem; 2008 Dec; 19(12):2462-70. PubMed ID: 19053298
[TBL] [Abstract][Full Text] [Related]
20. [
Li X; Yu W; Wollenweber T; Lu X; Wei Y; Beitzke D; Wadsak W; Kropf S; Wester HJ; Haug AR; Zhang X; Hacker M
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1616-1625. PubMed ID: 31004184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
